Scribe Therapeutics (SCRE) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on engineering in vivo CRISPR technologies for disease prevention and durable therapeutic intervention, targeting prevalent cardiovascular and metabolic diseases.

• Lead product candidate, STX-1150, uses proprietary ELXR epigenetic silencing technology to lower LDL-C without permanent genetic changes; initial clinical trial underway in Australia with data expected in 1H 2027.

• Pipeline includes STX-1200 (targeting Lp(a)) and STX-1400 (targeting APOC3), both leveraging XE gene-editing technology for durable, one-time treatments of lipid disorders.

• Strategic collaborations with Sanofi (rare genetic diseases) and Lilly (neurological/neuromuscular disorders) provide upfront, milestone, and royalty payments, validating platform versatility.

• Founded in 2017, the company has raised ~$150 million in equity financing and operates with a capital-efficient model, leveraging partnerships and grants.

Financial performance and metrics

• Collaboration revenue was $51.2M in 2025, up from $27.4M in 2024, driven by milestone achievements and workplan completions with partners.

• Net losses were $21.8M in 2025 and $47.8M in 2024; accumulated deficit reached $175.1M as of March 31, 2026.

• Cash, cash equivalents, and investments totaled $49.7M as of March 31, 2026; working capital was negative, and management raised substantial doubt about going concern status.

• Operating expenses in 2025 were $77.2M, with R&D accounting for $60.8M and G&A for $16.4M.

• Company expects to continue incurring losses and will require additional capital to fund operations beyond the current runway.

Use of proceeds and capital allocation

• Net proceeds from the IPO, combined with existing cash, will be used to advance STX-1150 through clinical development, progress STX-1200 and STX-1400, invest in pipeline and technology development, and for general corporate purposes.

• May allocate a portion of proceeds to in-license, acquire, or invest in complementary technologies or assets; no current commitments for such transactions.

• Proceeds are not expected to be sufficient to advance any program through regulatory approval; additional capital will be needed for full development and commercialization.